Ipsen S.A (I7G) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ipsen S.A (I7G) has a cash flow conversion efficiency ratio of 0.083x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€275.80 Million) by net assets (€3.34 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ipsen S.A - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Ipsen S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Ipsen S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ipsen S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Scentre Group
AU:SCG
|
0.031x |
|
CNA Financial Corporation
NYSE:CNA
|
0.064x |
|
First Financial Holding Co Ltd
TW:2892
|
-0.010x |
|
Neste Oyj
F:NEF
|
0.061x |
|
Penumbra Inc
NYSE:PEN
|
0.043x |
|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
0.119x |
|
Impala Platinum Holdings Ltd
JSE:IMP
|
0.047x |
|
Sterling Construction Company Inc
NASDAQ:STRL
|
0.167x |
Annual Cash Flow Conversion Efficiency for Ipsen S.A (2013–2024)
The table below shows the annual cash flow conversion efficiency of Ipsen S.A from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €4.18 Billion | €915.50 Million | 0.219x | -3.32% |
| 2023-12-31 | €3.82 Billion | €865.90 Million | 0.226x | -22.22% |
| 2022-12-31 | €3.34 Billion | €971.40 Million | 0.291x | -11.82% |
| 2021-12-31 | €2.75 Billion | €909.20 Million | 0.330x | -9.18% |
| 2020-12-31 | €2.12 Billion | €771.30 Million | 0.364x | +1.52% |
| 2019-12-31 | €1.75 Billion | €627.70 Million | 0.358x | +15.62% |
| 2018-12-31 | €1.84 Billion | €570.90 Million | 0.310x | +12.48% |
| 2017-12-31 | €1.54 Billion | €422.90 Million | 0.275x | +18.02% |
| 2016-12-31 | €1.36 Billion | €317.80 Million | 0.233x | +27.88% |
| 2015-12-31 | €1.23 Billion | €223.60 Million | 0.182x | -20.74% |
| 2014-12-31 | €1.07 Billion | €245.80 Million | 0.230x | +19.15% |
| 2013-12-31 | €973.70 Million | €188.10 Million | 0.193x | -- |
About Ipsen S.A
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more